XENE XENON PHARMACEUTICALS INC NPV | CA98420N1050
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 33.294.870 | 2.065.530 | 1511.93% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -5,03 | -4,81 | 4.53% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 16 | 16 | 0.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |